Welcome to our dedicated page for Entera Bio news (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio stock.
Entera Bio Ltd. (NASDAQ: ENTX) generates a steady flow of news as a clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. News coverage on this page focuses on the company’s progress with its proprietary N-Tab™ oral peptide platform and its pipeline of tablet-based biologic candidates.
Investors and followers of ENTX can use this news feed to track key developments around EB613, Entera Bio’s lead oral PTH(1-34) (teriparatide) osteoanabolic tablet for postmenopausal women with osteoporosis or low bone mineral density. Updates often include Phase 2 clinical data, post-hoc analyses of bone mineral density outcomes, presentations at bone and endocrine conferences, and regulatory milestones such as FDA alignment on Phase 3 trial design and acceptance of total hip BMD as a primary endpoint.
The news stream also highlights progress in the EB612 program for hypoparathyroidism, including preclinical pharmacokinetic and pharmacodynamic data for a proprietary long-acting PTH analog formulated as a once-daily oral tablet. Coverage extends to Entera Bio’s collaboration with OPKO Health on oral GLP-2 and oxyntomodulin tablet candidates, with reports on preclinical data for short bowel syndrome and obesity programs presented at international nutrition and endocrine meetings.
In addition, readers will find quarterly financial results, business updates, participation in healthcare and investor conferences, and commentary from company leadership on strategy and clinical priorities. This page brings together ENTX press releases and related announcements so that investors, clinicians and other stakeholders can follow the company’s clinical, regulatory and collaboration milestones in one place.
Entera Bio Ltd. (NASDAQ: ENTX) has appointed Spiros Jamas as its new CEO effective January 4, 2021, succeeding interim CEO Dr. Roger Garceau. Dr. Jamas brings over 30 years of biopharmaceutical experience, aiming to advance Entera’s osteoporosis treatment EB613 and hypoparathyroidism treatment EB612, both in Phase 2 trials. The company anticipates key data readouts in the first half of 2021, presenting potential growth opportunities. Shareholder approval is required for Dr. Jamas' engagement terms.
Entera Bio Ltd. (NASDAQ: ENTX) announced the completion of enrollment in its Phase 2 clinical trial of EB613, aimed at treating osteoporosis. A total of 161 subjects were randomized, with interim data showing a 2.15% mean increase in lumbar spine bone mineral density (BMD) compared to placebo. The company plans to report additional biomarker data in Q1 and Q2 of 2021. Financially, Entera reported revenues of $144,000 for the nine months ended September 30, 2020, alongside an operating loss of $(8.8) million and a net loss of $(7.7) million. Cash reserves stood at $7.1 million as of September 30, 2020.
Entera Bio Ltd. (NASDAQ: ENTX) will release its business and financial results for Q3 2020 on November 19, 2020, before U.S. markets open. The management team will host a conference call at 8:30 a.m. ET on that day to discuss the results, with a Q&A session to follow. Participants can join the call by dialing (855) 547-3865 within the U.S. or (409) 217-8787 internationally, using the conference ID 9495026. A live audio webcast will also be available on Entera's website.
Entera Bio Ltd. (NASDAQ: ENTX) announced the completion of enrollment in its Phase 2 clinical trial for EB613, an oral treatment for osteoporosis. This study involves 161 postmenopausal women and aims to evaluate the drug's effect on bone mineral density (BMD). Interim results showed a placebo-adjusted BMD increase of 2.15% in the highest dose group. Full biomarker data is expected in Q1 2021, with final results due in Q2 2021. Entera has $7.1 million in cash, sufficient to support operations into the second quarter of 2021, despite challenges from COVID-19.
Entera Bio Ltd. (NASDAQ: ENTX) announced a virtual presentation at the H.C. Wainwright Annual Israel Conference on November 12, 2020 at 8:00 a.m. ET. The event will showcase its advancements in orally delivered large molecule therapeutics, targeting unmet medical needs in healthcare.
Entera’s proprietary technology addresses challenges in drug absorption, focusing on its lead candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, currently in Phase 2 clinical development.
Entera Bio Ltd. (NASDAQ: ENTX) will participate virtually in the H.C. Wainwright Global Investment Conference on September 15, 2020, at 3:00 p.m. EDT. Investors can access a live webcast of the presentation via the company’s website, with a replay available for 45 days after. Entera specializes in the development of orally delivered large molecule therapeutics for conditions like osteoporosis and hypoparathyroidism, leveraging proprietary technology to improve absorption and delivery. The company's candidates EB613 and EB612 are currently in Phase 2 clinical trials.
Entera Bio Ltd. (NASDAQ: ENTX) announced promising interim data from its Phase 2 clinical trial of EB613, an oral treatment for osteoporosis. The 6-month results demonstrated a mean placebo-adjusted increase of 2.15% in lumbar spine bone mineral density (BMD) for the 1.5 mg treatment group. With 131 subjects currently enrolled, the company expects to complete enrollment by Q3 2020. Financially, Entera reported revenues of $94,000 and an operating loss of $6.4 million for the first half of 2020, an increase from the previous year. Cash reserves stood at $9.8 million, sufficient to cover operations into Q2 2021.
Entera Bio Ltd. (NASDAQ: ENTX) will report its business and financial results for Q2 2020 on August 20, 2020, before U.S. markets open. A conference call is scheduled for 8:30 a.m. EDT on the same day, featuring management's discussion followed by a Q&A session. Participants can dial (855) 547-3865 (US) or (409) 217-8787 (international) with the ID '5243229'. Entera focuses on developing orally delivered large molecule therapeutics, including EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 trials.
Entera Bio Ltd. (NASDAQ: ENTX) announced its participation in the BTIG Biotechnology Conference on August 10, 2020, at 12:30 p.m. EDT. The event will be available via a live webcast on the company's Investor Relations page. A replay will be accessible for 45 days post-presentation.
Entera specializes in orally delivered macromolecule therapeutics addressing significant medical needs, particularly for patients who struggle with injectable therapies. Their leading candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 clinical development.
Summary not available.
FAQ
What is the current stock price of Entera Bio (ENTX)?
What is the market cap of Entera Bio (ENTX)?
